Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04390763
Registration number
NCT04390763
Ethics application status
Date submitted
14/05/2020
Date registered
18/05/2020
Date last updated
28/05/2025
Titles & IDs
Public title
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Query!
Scientific title
A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Query!
Secondary ID [1]
0
0
2020-000349-14
Query!
Secondary ID [2]
0
0
CNIS793B12201
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
daNIS-1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metastatic Pancreatic Ductal Adenocarcinoma
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - NIS793
Treatment: Other - Spartalizumab
Treatment: Drugs - gemcitabine
Treatment: Drugs - nab-paclitaxel
Experimental: Safety Run-in - Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
Experimental: Randomized Arm 1 - Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
Experimental: Randomized Arm 2 - Combination of NIS793 + gemcitabine + nab-paclitaxel
Active comparator: Randomized Arm 3 - gemcitabine + nab-paclitaxel
Treatment: Other: NIS793
anti-TGFb antibody. NIS793 2100 mg every 2 weeks by intravenous (i.v.) infusion.
Treatment: Other: Spartalizumab
anti-PD-1 antibody. spartalizumab 400 mg every 4 weeks by i.v. infusion.
Treatment: Drugs: gemcitabine
SOC chemotherapy. Gemcitabine (1000 mg/m\^2 on Days 1, 8, and 15) i.v. given as per label.
Treatment: Drugs: nab-paclitaxel
SOC chemotherapy. Nab-paclitaxel (125 mg/m\^2 on Days 1, 8, and 15) i.v. given as per label.
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Safety run-in Part: Number of Participants With Dose-Limiting Toxicities (DLTs)
Query!
Assessment method [1]
0
0
A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade = 3 where the relationship to study treatment cannot be ruled out and is not clearly related solely to disease, disease progression, inter-current illness or concomitant medications, which occurs within the DLT evaluation period. The DLT evaluation period is the first 28 days of treatment with NIS793 with spartalizumab in combination with gemcitabine/nab-paclitaxel. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.
Query!
Timepoint [1]
0
0
First cycle of treatment (28 days)
Query!
Primary outcome [2]
0
0
Safety run-in Part: Number of Participants With AEs and SAEs During the On-treatment Period
Query!
Assessment method [2]
0
0
Number of participants with AEs (any adverse events regardless of seriousness) and serious adverse events (SAEs), including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs. AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. For CTCAE v5.0, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE. The on-treatment period is defined from the day of first administration of any study treatment up to 30 days after the date of the last actual administration of any study drug.
Query!
Timepoint [2]
0
0
Up to approximately 0.8 years
Query!
Primary outcome [3]
0
0
Safety run-in Part: Number of Participants With Dose Reductions and Dose Interruptions of NIS793, Spartalizumab, Gemcitabine and Nab-paclitaxel
Query!
Assessment method [3]
0
0
Number of participants with at least one dose reduction and at least one dose interruption of study drugs. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule. No dose reductions were allowed for NIS793 and spartalizumab beyond the first 28 days period of Safety run-in part.
Query!
Timepoint [3]
0
0
Up to approximately 0.7 years
Query!
Primary outcome [4]
0
0
Safety run-in Part: Dose Intensity of NIS793 and Spartalizumab
Query!
Assessment method [4]
0
0
Dose intensity of NIS973 and spartalizumab was calculated as cumulative actual dose in milligrams divided by duration of exposure in days and multiplied by 28 days. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule.
Query!
Timepoint [4]
0
0
Cycle 1 and Cycle 3. The duration of each cycle was 28 days.
Query!
Primary outcome [5]
0
0
Safety run-in Part: Dose Intensity of Gemcitabine and Nab-paclitaxel
Query!
Assessment method [5]
0
0
Dose intensity of gemcitabine and nab-paclitaxel was calculated as cumulative actual dose in milligrams/m\^2 divided by duration of exposure in days and multiplied by 28 days.
Query!
Timepoint [5]
0
0
Cycle 1 and Cycle 3. The duration of each cycle was 28 days.
Query!
Primary outcome [6]
0
0
Randomized Part: Progression-Free Survival (PFS) Per RECIST v1.1 - Bayesian Model
Query!
Assessment method [6]
0
0
PFS was based on local review of tumor assessments, using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria. PFS is defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. If a subject had not had an event, PFS was censored at the date of last adequate tumor assessment. PFS was estimated using a Bayesian model. For each comparison (arm 1 versus arm 3 and arm 2 versus arm 3), PFS was modeled using a two-piece hazard model, with specifying hazard rates before and after the possible delayed effect for arms 1 and 2 and constant hazard rate for arm 3. Results in the table as expressed as estimated posterior median hazard rate and one-sided 90% credible interval.
Query!
Timepoint [6]
0
0
Up to approximately 2 years. Risk changing timepoint=approximately 0.3 years.
Query!
Primary outcome [7]
0
0
Randomized Part: Progression-Free Survival (PFS) Per RECIST v1.1 - Kaplan-Meier Curves and Cox Model
Query!
Assessment method [7]
0
0
PFS was based on local review of tumor assessments, using RECIST 1.1 criteria. PFS is defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. If a subject had not had an event, PFS was censored at the date of last adequate tumor assessment. PFS was analyzed based on the Kaplan-Meier curves and the Cox model.
Query!
Timepoint [7]
0
0
Up to approximately 2 years
Query!
Secondary outcome [1]
0
0
Randomized Part: Number of Participants With AEs and SAEs During the On-treatment Period
Query!
Assessment method [1]
0
0
Number of participants with AEs (any adverse events regardless of seriousness) and serious adverse events (SAEs), including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs. AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. For CTCAE v5.0, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE. The on-treatment period is defined from the day of first administration of any study treatment up to 30 days after the date of the last actual administration of any study drug.
Query!
Timepoint [1]
0
0
Up to approximately 1.8 years
Query!
Secondary outcome [2]
0
0
Randomized Part: Number of Participants With Dose Reductions and Dose Interruptions of NIS793, Spartalizumab, Gemcitabine and Nab-paclitaxel
Query!
Assessment method [2]
0
0
Number of participants with at least one dose reduction and at least one dose interruption of study drugs. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule. No dose reductions were allowed for NIS793 and spartalizumab in the Randomized part.
Query!
Timepoint [2]
0
0
Up to approximately 1.7 years
Query!
Secondary outcome [3]
0
0
Randomized Part: Dose Intensity of NIS973 and Spartalizumab
Query!
Assessment method [3]
0
0
Dose intensity of NIS973 and spartalizumab was calculated as cumulative actual dose in milligrams divided by duration of exposure in days and multiplied by 28 days. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule.
Query!
Timepoint [3]
0
0
Cycle 1 and Cycle 3. The duration of each cycle was 28 days
Query!
Secondary outcome [4]
0
0
Randomized Part: Dose Intensity of Gemcitabine and Nab-paclitaxel
Query!
Assessment method [4]
0
0
Dose intensity of gemcitabine and nab-paclitaxel was calculated as cumulative actual dose in milligrams/m\^2 divided by duration of exposure in days and multiplied by 28 days.
Query!
Timepoint [4]
0
0
Cycle 1 and Cycle 3. The duration of each cycle was 28 days
Query!
Secondary outcome [5]
0
0
Randomized Part: Overall Response Rate (ORR) Per RECIST v1.1
Query!
Assessment method [5]
0
0
ORR is the percentage of patients with a confirmed best overall response of complete response (CR) or partial response (PR), based on local investigator assessment per Response Evaluation Criteria for Solid Tumors (RECIST) v1.1. For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [5]
0
0
Up to approximately 1.7 years
Query!
Secondary outcome [6]
0
0
Randomized Part: Duration of Response (DOR) Per RECIST v1.1
Query!
Assessment method [6]
0
0
DOR per RECIST v1.1 is defined as the time from the first documented response of CR or PR to the date of the first documented progression or death. DOR only applies to patients with a best overall response of CR or PR by investigator assessment per RECIST v1.1. Participants continuing without progression or death were censored at the date of their last adequate tumor assessment. DOR was analyzed using the Kaplan-Meier method.
Query!
Timepoint [6]
0
0
Up to approximately 1.7 years
Query!
Secondary outcome [7]
0
0
Randomized Part: Time to Progression (TTP) Per RECIST v1.1
Query!
Assessment method [7]
0
0
TTP per RECIST v1.1 is defined as the time from the date of randomization to the date of event defined as the first documented progression per RECIST v1.1 or death due to underlying cancer. If a participant had no progression or death, the participant was censored at the date of last adequate tumor assessment. DOR was analyzed using the Kaplan-Meier method.
Query!
Timepoint [7]
0
0
Up to approximately 1.7 years
Query!
Secondary outcome [8]
0
0
Randomized Part: Overall Survival (OS)
Query!
Assessment method [8]
0
0
Overall survival is defined as the time from the date of randomization to the date of death due to any cause. OS was analyzed using the Kaplan-Meier method.
Query!
Timepoint [8]
0
0
Up to approximately 2 years
Query!
Secondary outcome [9]
0
0
Randomized Part: Change From Baseline in PD-L1 Expression
Query!
Assessment method [9]
0
0
The tumor expression of programmed cell death-ligand 1 (PD-L1) was measured by immunohistochemical methods. Results are expressed as absolute change from baseline in PD-L1 expression.
Query!
Timepoint [9]
0
0
Baseline (Screening), on-treatment (anytime between Cycle 3 Day 2 and Day 4). The duration of each cycle was 28 days.
Query!
Secondary outcome [10]
0
0
Randomized Part: Change From Baseline in CD8 Expression
Query!
Assessment method [10]
0
0
The tumor expression of CD8 was measured by immunohistochemical methods. Results are expressed as absolute change from baseline in CD8 expression.
Query!
Timepoint [10]
0
0
Baseline (Screening), on-treatment (anytime between Cycle 3 Day 2 and Day 4). The duration of each cycle was 28 days.
Query!
Secondary outcome [11]
0
0
Randomized Part: Number of Participants With Anti-NIS793 Antibodies
Query!
Assessment method [11]
0
0
The immunogenicity (IG) against NIS793 was assessed in serum using a validated enhanced electrochemiluminescence immunoassay (ECLIA). Patient anti-drug antibodies (ADA) status was defined as follows: * ADA-negative at baseline: ADA-negative sample at baseline * ADA-positive at baseline: ADA-positive sample at baseline * ADA-negative post-baseline: patient with ADA-negative sample at baseline and at least 1 post baseline sample, all of which are ADA-negative samples * ADA-inconclusive post-baseline = patient who does not qualify as ADA-positive or ADA-negative post-baseline * Treatment-induced ADA-positive = ADA-negative sample at baseline and at least 1 treatment-induced ADA-positive sample
Query!
Timepoint [11]
0
0
Baseline (before first dose) and post-baseline (assessed throughout the treatment up to approximately 1.7 years)
Query!
Secondary outcome [12]
0
0
Randomized Part: Number of Participants With Anti-spartalizumab Antibodies
Query!
Assessment method [12]
0
0
The immunogenicity (IG) against spartalizumab was assessed in serum using a validated a validated homogenous enzyme-linked immunosorbent assay (ELISA). Patient anti-drug antibodies (ADA) status was defined as follows: * ADA-negative at baseline: ADA-negative sample at baseline * ADA-inconclusive at baseline: patient who does not qualify as ADA-positive or ADA-negative at baseline * ADA-positive at baseline: ADA-positive sample at baseline * ADA-negative post-baseline: patient with ADA-negative sample at baseline and at least 1 post baseline sample, all of which are ADA-negative samples * ADA-inconclusive post-baseline = patient who does not qualify as ADA-positive or ADA-negative post-baseline * Treatment-induced ADA-positive = ADA-negative sample at baseline and at least 1 treatment-induced ADA-positive sample
Query!
Timepoint [12]
0
0
Cycle 1 and Cycle 3. The duration of each cycle was 28 days
Query!
Secondary outcome [13]
0
0
Randomized Part: Maximum Observed Serum Concentration (Cmax) of NIS793
Query!
Assessment method [13]
0
0
Pharmacokinetic (PK) parameters were calculated based on NIS793 serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
Query!
Timepoint [13]
0
0
Cycle 1 and Cycle 3: pre-dose, 1, 24, 168 and 336 hours after the end of the infusion on Day 1. The duration of the infusion was 30 minutes. One cycle=28 days
Query!
Secondary outcome [14]
0
0
Randomized Part: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of NIS793
Query!
Assessment method [14]
0
0
PK parameters were calculated based on NIS793 serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.
Query!
Timepoint [14]
0
0
Cycle 1 and Cycle 3: pre-dose, 1, 24, 168 and 336 hours after the end of the infusion on Day 1. The duration of the infusion was 30 minutes. One cycle=28 days
Query!
Secondary outcome [15]
0
0
Randomized Part: Trough Serum Concentration (Ctrough) of NIS793
Query!
Assessment method [15]
0
0
Ctrough is defined as the concentration reached immediately before the next dose is administered. All drug concentrations below the lower limit of quantification were treated as zero for the calculation of PK parameters.
Query!
Timepoint [15]
0
0
Cycle 1: pre-dose on Day 1. Cycle 3: pre-dose on Day 1 and Day 15 (combined). One cycle=28 days
Query!
Secondary outcome [16]
0
0
Randomized Part: Maximum Observed Serum Concentration (Cmax) of Spartalizumab
Query!
Assessment method [16]
0
0
PK parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
Query!
Timepoint [16]
0
0
Cycle 1 and Cycle 3: pre-dose, 1, 24, 168 and 648 hours after the end of the infusion on Day 1. The duration of the infusion was 30 minutes. One cycle=28 days
Query!
Secondary outcome [17]
0
0
Randomized Part: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Spartalizumab
Query!
Assessment method [17]
0
0
PK parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.
Query!
Timepoint [17]
0
0
Cycle 1 and Cycle 3: pre-dose, 1, 24, 168 and 648 hours after the end of the infusion on Day 1. The duration of the infusion was 30 minutes. One cycle=28 days
Query!
Secondary outcome [18]
0
0
Randomized Part: Trough Serum Concentration (Ctrough) of Spartalizumab
Query!
Assessment method [18]
0
0
Ctrough is defined as the concentration reached immediately before the next dose is administered. All drug concentrations below the lower limit of quantification were treated as zero for the calculation of PK parameters.
Query!
Timepoint [18]
0
0
Cycle 2, 3 and 4: pre-dose on Day 1. One cycle=28 days
Query!
Secondary outcome [19]
0
0
Randomized Part: Maximum Observed Plasma Concentration (Cmax) of Gemcitabine
Query!
Assessment method [19]
0
0
PK parameters were calculated based on gemcitabine plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
Query!
Timepoint [19]
0
0
Cycle 1 and Cycle 4: pre-dose, end of infusion, and 2, 3, 5 and 24 hours after the start of infusion on Day 1. The duration of the infusion was according to the product labelling and local guidance. One cycle=28 days
Query!
Secondary outcome [20]
0
0
Randomized Part: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Gemcitabine
Query!
Assessment method [20]
0
0
PK parameters were calculated based on gemcitabine plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.
Query!
Timepoint [20]
0
0
Cycle 1 and Cycle 4: pre-dose, end of infusion, and 2, 3, 5 and 24 hours after the start of infusion on Day 1. The duration of the infusion was according to the product labelling and local guidance. One cycle=28 days
Query!
Secondary outcome [21]
0
0
Randomized Part: Trough Serum Concentration (Ctrough) of Gemcitabine
Query!
Assessment method [21]
0
0
Ctrough is defined as the concentration reached immediately before the next dose is administered. All drug concentrations below the lower limit of quantification were treated as zero for the calculation of PK parameters.
Query!
Timepoint [21]
0
0
Cycle 4: pre-dose on Day 1. One cycle=28 days
Query!
Secondary outcome [22]
0
0
Randomized Part: Maximum Observed Plasma Concentration (Cmax) of Nab-paclitaxel
Query!
Assessment method [22]
0
0
PK parameters were calculated based on nab-paclitaxel plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
Query!
Timepoint [22]
0
0
Cycle 1 and Cycle 4: pre-dose, end of infusion, and 2, 3, 5 and 24 hours after the start of infusion on Day 1. The duration of the infusion was according to the product labelling and local guidance. One cycle=28 days
Query!
Secondary outcome [23]
0
0
Randomized Part: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Nab-paclitaxel
Query!
Assessment method [23]
0
0
PK parameters were calculated based on nab-paclitaxel plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.
Query!
Timepoint [23]
0
0
Cycle 1 and Cycle 4: pre-dose, end of infusion, and 2, 3, 5 and 24 hours after the start of infusion on Day 1. The duration of the infusion was according to the product labelling and local guidance. One cycle=28 days
Query!
Secondary outcome [24]
0
0
Randomized Part: Trough Serum Concentration (Ctrough) of Nab-paclitaxel
Query!
Assessment method [24]
0
0
Ctrough is defined as the concentration reached immediately before the next dose is administered. All drug concentrations below the lower limit of quantification were treated as zero for the calculation of PK parameters.
Query!
Timepoint [24]
0
0
Cycle 4: pre-dose on Day 1. One cycle=28 days
Query!
Eligibility
Key inclusion criteria
1. Signed informed consent must be obtained prior to participation in the study.
2. Male or female = 18 years of age at the time of informed consent.
3. Participants with histologically or cytologically confirmed treatment-naïve metastatic adenocarcinoma of the pancreas with measurable disease as per RECIST 1.1.
4. Participants must have a site of disease amenable to biopsy, and be candidate for tumor biopsy according to the treating institution's guidelines. Participants must be willing to undergo a tumor biopsy at screening and during therapy on the study. In the event a new biopsy cannot be safely performed at study entry, an archival sample (collected <6 months prior) may be substituted following documented discussion with Novartis.
5. ECOG performance status = 1.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
100
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Previous radiotherapy, surgery (with exception of placement of biliary stent, which is allowed), chemotherapy or any other investigational therapy for the treatment of metastatic pancreatic cancer. Participants having received previous chemotherapy in the adjuvant setting.
2. Participants amenable to potentially curative resection.
3. Participants with a diagnosis of pancreatic neuroendocrine tumors (NETs), acinar, or islet cell tumors.
4. Having out of range laboratory values as pre-defined in the protocol.
5. Participants with MSI-H pancreatic adenocarcinoma.
6. Presence of symptomatic CNS metastases, or CNS metastases that require local CNS directed therapy (such as radiotherapy or surgery), or increasing doses of corticosteroids 2 weeks prior to study entry.
7. History of severe hypersensitivity reactions to any ingredient of study drug(s) and other mAbs and/or their excipients.
8. The participant exhibits any of the events outlined in the contra-indications or special warnings and precautions sections of gemcitabine and nab-paclitaxel as per locally approved labels.
9. Impaired cardiac function or clinically significant cardiac disease.
10. Known history of testing positive HIV infection.
11. Active HBV or HCV infection. Participants whose disease is controlled under antiviral therapy should not be excluded.
12. History of or current interstitial lung disease or pneumonitis grade = 2
13. High risk of clinically significant gastrointestinal tract bleeding or any other condition associated with or history of significant bleeding.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/10/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
2/05/2024
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
164
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Westmead
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [2]
0
0
3000 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Georgia
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Maryland
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Massachusetts
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Pennsylvania
Query!
Country [5]
0
0
Austria
Query!
State/province [5]
0
0
Salzburg
Query!
Country [6]
0
0
Austria
Query!
State/province [6]
0
0
Wien
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
Liege
Query!
Country [8]
0
0
Czechia
Query!
State/province [8]
0
0
Czech Republic
Query!
Country [9]
0
0
Finland
Query!
State/province [9]
0
0
Helsinki
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Paris 10
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Toulouse 4
Query!
Country [12]
0
0
Germany
Query!
State/province [12]
0
0
Essen
Query!
Country [13]
0
0
Germany
Query!
State/province [13]
0
0
Heidelberg
Query!
Country [14]
0
0
Germany
Query!
State/province [14]
0
0
Ulm
Query!
Country [15]
0
0
Italy
Query!
State/province [15]
0
0
MI
Query!
Country [16]
0
0
Italy
Query!
State/province [16]
0
0
VR
Query!
Country [17]
0
0
Singapore
Query!
State/province [17]
0
0
Singapore
Query!
Country [18]
0
0
Spain
Query!
State/province [18]
0
0
Catalunya
Query!
Country [19]
0
0
Spain
Query!
State/province [19]
0
0
Madrid
Query!
Country [20]
0
0
Switzerland
Query!
State/province [20]
0
0
St Gallen
Query!
Country [21]
0
0
Switzerland
Query!
State/province [21]
0
0
Zuerich
Query!
Country [22]
0
0
Taiwan
Query!
State/province [22]
0
0
Taichung
Query!
Country [23]
0
0
Taiwan
Query!
State/province [23]
0
0
Taipei
Query!
Country [24]
0
0
United Kingdom
Query!
State/province [24]
0
0
Oxford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in previously untreated mPDAC.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04390763
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/63/NCT04390763/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/63/NCT04390763/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT04390763
Download to PDF